Trials / Completed
CompletedNCT02170662
Topical Bimatoprost Effect on Androgen Dependent Hair Follicles
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Duke University · Academic / Other
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effect of bimatoprost solution on scalp hair growth. Bimatoprost 0.03% ophthalmic solution is currently approved by the FDA for treatment of glaucoma (Lumigan™) and for thickening of thin eyelashes (Latisse™). Bimatoprost 0.03% is not approved for the treatment of scalp hair loss and its use in this study is considered investigational which means it is still being tested in research studies. Thirty-three subjects were consented and screened, 9 entered and 9 completed the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimatoprost | Bimatoprost 0.03% ophthalmic solution as purchased from the manufacturer will be the active drug. |
| DRUG | Placebo |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2011-05-01
- Completion
- 2011-05-01
- First posted
- 2014-06-23
- Last updated
- 2014-09-05
- Results posted
- 2014-08-20
Source: ClinicalTrials.gov record NCT02170662. Inclusion in this directory is not an endorsement.